NASDAQ:DBVT DBV Technologies Q2 2025 Earnings Report $14.70 0.00 (0.00%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$14.27 -0.43 (-2.93%) As of 04:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast DBV Technologies EPS ResultsActual EPS-$1.55Consensus EPS -$0.21Beat/MissMissed by -$1.34One Year Ago EPSN/ADBV Technologies Revenue ResultsActual Revenue$1.74 millionExpected Revenue$0.64 millionBeat/MissBeat by +$1.09 millionYoY Revenue GrowthN/ADBV Technologies Announcement DetailsQuarterQ2 2025Date7/29/2025TimeBefore Market OpensConference Call DateTuesday, July 29, 2025Conference Call Time4:00PM ETConference Call ResourcesPress ReleaseQuarterly Report (10-Q)Interim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress ReleaseQuarterly report(10-Q)Interim report DBV Technologies Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and Kalaris Therapeutics (KLRS)July 18 at 12:19 PM | theglobeandmail.comDBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of SalesJuly 17 at 5:00 PM | globenewswire.comEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election, and the Covid crisis - is now warning investors to prepare for a historic mid-term meltdown. Rickards outlines three specific steps he says everyday investors should take before things turn ugly. Those who act early may avoid the losses that could wipe out millions of unprepared portfolios.July 20 at 1:00 AM | Paradigm Press (Ad)DBV Technologies Announces the Filing of its 2026 Half-Year Report ? Conditions for Accessing or Consulting the ReportJuly 16, 2026 | tmcnet.comDBV Technologies S.A. (DBVT) Q2 2026 Earnings Call TranscriptJuly 16, 2026 | seekingalpha.comDBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the ReportJuly 16, 2026 | globenewswire.comSee More DBV Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email. Email Address About DBV TechnologiesDBV Technologies (NASDAQ:DBVT) SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies. The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents. Viaskin Peanut is being evaluated in global clinical trials to assess its ability to reduce allergic reactions and improve patients’ threshold of reactivity to peanut exposure. DBV is also exploring the applicability of its technologies to other food allergens, including cow’s milk and egg, as part of its long-term pipeline strategy. Founded in 2002 and headquartered in Montrouge, France, DBV Technologies maintains research and development operations in Cambridge, Massachusetts, reflecting its transatlantic focus. The company has established alliances with academic institutions and leading allergy research centers to advance its clinical programs and expand its scientific expertise. Its development activities span North America, Europe and other regions where food allergy represents a significant public health challenge. Under the leadership of President and Chief Executive Officer Daniel Tasse, DBV Technologies has navigated multiple phases of clinical development and regulatory interactions. The company continues to engage with health authorities to define approval pathways and to establish its proprietary immunotherapy platform as a new standard of care for allergic diseases. View DBV Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitThe Market Sold Alcoa After Earnings—But It May Be Missing the Real StoryTSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthWhy Intuitive Surgical’s Strong Quarter Still Spooked InvestorsNetflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
